Vestibular schwannoma (VS) is a benign Schwann cell-derived tumor that frequently causes progressive hearing loss and vestibulocochlear dysfunction, substantially impacting quality of life. The molecular mechanisms underlying VS pathobiology remain poorly defined, and reliable biomarkers or targeted therapies are lacking....
No actionable change at this time; findings are preclinical and exploratory, with no validated therapeutic targets ready for clinical use.
Identifying dysregulated molecular pathways in vestibular schwannoma through transcriptomic meta-analysis may accelerate the development of targeted medical therapies, potentially offering alternatives to surgery or radiation for patients with progressive hearing loss.
- 01Transcriptomic meta-analysis pooled gene-expression data across multiple vestibular schwannoma datasets.
- 02Several dysregulated molecular pathways linked to tumor growth and vestibulocochlear dysfunction were identified.
- 03Potential drug targets were highlighted, though none are clinically validated yet.
- 04Findings have implications for understanding progressive hearing loss associated with vestibular schwannoma.
- 05Study published in PLOS ONE (DOI: 10.1371/journal.pone.0353343).
Transcriptomic meta-analysis can identify dysregulated pathways and potential therapeutic targets in vestibular schwannoma.
studypartially supportedVestibular schwannoma is associated with progressive hearing loss and vestibulocochlear dysfunction.
studysupported- PMID
- 42430393
- DOI
- 10.1371/journal.pone.0353343.
- Journal
- PLOS ONE
- Publication type
- meta_analysis
- Evidence level
- 2a
- Population
- Transcriptomic datasets from vestibular schwannoma tissue samples
- Intervention
- Transcriptomic meta-analysis of gene expression in vestibular schwannoma
Primary outcomes
Identification of dysregulated molecular pathways in vestibular schwannoma; Identification of potential therapeutic targets